Carl Zeiss Meditec Shares Face Multifaceted Challenges

The dividend payment date for Carl Zeiss Meditec shareholders arrived amid a decidedly somber market atmosphere. The distribution of €0.55 per share, a reduction from the previous year's €0.60, coincided with the stock trading perilously close to its lowest point in 52 weeks. This paints a stark picture of the current difficulties facing the medical technology firm.

China: The Core Challenge

The company's struggles are inextricably linked to its performance in China, a market that accounts for approximately one-quarter of total group revenue and stands as its most significant single country market. While an exit from China is not under consideration, the road to recovery remains uncertain. According to DZ Bank analyst Sven Kürten, a bottom may be forming, but a sustained rebound is not yet assured.

Compounding the issue, a new nationwide tender process for intraocular lenses is expected to trigger substantial price pressure, driven by intensified local competition. In response, Carl Zeiss Meditec is planning to shift more production capacity to China—a strategic move that could have implications for its operational footprint in Germany.

Should investors sell immediately? Or is it worth buying Carl Zeiss Meditec?

First Quarter Results Reveal Severe Pressure

The initial quarter of the 2025/26 fiscal year provided little cause for optimism. Revenue declined by 4.8% year-over-year to €467 million. More alarming was the dramatic erosion in profitability. The EBITA margin collapsed to 1.7%, a sharp fall from 7.2% in the prior-year period. Consequently, the quarter ended with a net loss of €4.9 million, a stark reversal from the €15.7 million profit recorded twelve months earlier.

In reaction to these figures, DZ Bank made a significant adjustment ahead of the annual general meeting. Analyst Sven Kürten slashed the fair value estimate from €42 to €26 per share. He emphasized the considerable pressure on management to present concrete new targets and strategic measures with the upcoming half-year report on May 12. The bank's rating on the stock remains "Hold."

All Eyes on the Mid-Year Report

Management had already withdrawn its original full-year forecast in January, which had projected revenue of around €2.3 billion and an EBITA margin of 12.5%. The market now anticipates updated guidance to be released no later than the publication of the half-year figures on May 12. This report is widely viewed as a critical indicator of the company's near-term trajectory.

Current analyst consensus reflects the pervasive uncertainty surrounding the stock, with an average price target of €33.69. The range of estimates is broad, spanning from €22.40 to €30.00, underscoring the lack of clear direction until the company provides its updated strategic roadmap.

Ad

Carl Zeiss Meditec Stock: New Analysis - 31 March

Fresh Carl Zeiss Meditec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Carl Zeiss Meditec analysis...

DE0005313704 | CARL | boerse | 69033987 |